(June 18, 2024, 3:07 PM EDT) -- WILMINGTON, Del. — A Federal Circuit U.S. Court of Appeals judge, visiting in the U.S. District Court for the District of Delaware, said that a recent decision by a panel of his court that reversed and remanded findings that a patented schizophrenia drug is nonobvious won’t prompt him to revisit his own findings in a separate case that confirmed the same formulation as patentable....